Skip to content
Clinical Trials – home
SpainBack to Spain

Clinical trials in Terrassa – page 120

3 744 clinical trials in Terrassa, Spain across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Terrassa at a glance
3 744
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

3 744 trials in Terrassa

Open in trial search

Safety and efficacy of efimosfermin alfa versus placebo in adults with compensated cirrhosis (stage F4) due to MASH

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Non-small cell lung cancer+1

Not yet recruiting

Study of setidegrasib (ASP3082) and docetaxel in patients with KRAS G12D‑mutated advanced/metastatic NSCLC after platinum chemo and checkpoint inhibitor

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:ASP3082
  • Sponsor:Astellas Pharma Global Development Inc.

Breast cancer+1

Not yet recruiting

Long‑term safety study of alpelisib alone or with fulvestrant in adults with breast cancer who benefited from previous alpelisib treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Novartis Pharma AG

Study of efimosfermin alfa versus placebo in adults with compensated cirrhosis from metabolic dysfunction-associated steatohepatitis (MASH)

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Adenocarcinoma pancreas

Not yet recruiting

First‑Line Study of Zoldonrasib (RMC‑9805) Drug Combination vs Gemcitabine/Nab‑Paclitaxel in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Daraxonrasib
  • Sponsor:Revolution Medicines Inc.

A Phase 2 Study of LAD603 in Adults with Systemic Lupus Erythematosus and Active Skin Rash

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:LAD603
  • Sponsor:Almirall S.A.

Plasma cell myeloma

Not yet recruiting

A Phase III Study of AZD0120 versus melphalan hydrochloride with lenalidomide maintenance in transplant‑eligible adults with newly diagnosed multiple myeloma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:AZD0120
  • Sponsor:AstraZeneca AB

Safety and Efficacy of Extended‑Release Tacrolimus (VI‑0106) in Adults with Pulmonary Arterial Hypertension and Functional Limitations

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Tacrolimus
  • Sponsor:Vivus B.V.

Primary biliary cholangitis

Not yet recruiting

Safety and Efficacy of Saroglitazar Magnesium in Patients with Primary Biliary Cholangitis: A Long‑Term Randomized Placebo‑Controlled Study

Investigational
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Saroglitazar hemimagnesium
  • Sponsor:Zydus Therapeutics Inc.

Diffuse large B-cell lymphoma+5

Not yet recruiting

Study of MDX2003 in Adults with Relapsed or Refractory B‑Cell Malignancies

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:MDX2003
  • Sponsor:Modex Therapeutics Inc.

Breast cancer

Not yet recruiting

Effect of linzagolix and bilastine on breast density in premenopausal women at high risk of breast cancer: a phase II trial

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Bilastine
  • Sponsor:Consorci Mar Parc De Salut De Barcelona

Crohn's disease

Not yet recruiting

Evaluation of Upadacitinib for Reducing Ileal Strictures in Patients with Crohn’s Disease

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:UZ Leuven

Other cities in Spain

The busiest research cities in the country

All 210 cities in Spain

Clinical research in Terrassa

What the registry says about research in the country

01 Oncology Research

Groundbreaking studies focusing on multiple myeloma, breast cancer, and prostate cancer treatments. Innovative combination therapies and targeted approaches are being evaluated for improved patient outcomes.

  • Gastrectomy procedures for cancer treatment
  • HER2-positive breast cancer therapies
  • Advanced prostate cancer management

Studies include novel immunotherapy combinations and precision medicine approaches.

02 Immunology and Allergies

Clinical trials investigating immunotherapy treatments for various allergic conditions, including advanced research in rhinitis and rhinoconjunctivitis management.

  • House dust mite allergies
  • Cupressaceae pollen sensitivity
  • Combined allergy treatments

Focus on developing targeted allergen-specific treatments for improved quality of life.

03 Neurology and Mental Health

Innovative research into Parkinson's Disease and Alzheimer's Disease, exploring new therapeutic approaches and disease-modifying treatments.

  • Early-stage Alzheimer's interventions
  • Parkinson's Disease management
  • Seizure control therapies

Studies emphasize long-term safety and efficacy of novel therapeutic agents.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.